SCHEMBL3669381

SCHEMBL3669381

CC1CN(c2nnc(Cl)c3ccccc23)CCN1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
GFER P55789 1/20 0.55
PKM P14618 1/20 0.46
TSHR P16473 1/20 0.46
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
MAPK14 Q16539 1/20 0.43
ALDH1A1 P00352 3/20 0.43
POLB P06746 1/20 0.43
KHK P50053 2/20 0.42
KIT P10721 1/20 0.41
HRH4 Q9H3N8 2/20 0.41
HPGD P15428 1/20 0.40
LMNA P02545 1/20 0.40
ADRA2A P08913 1/20 0.39
ADRA2B P18089 1/20 0.39
ADRA2C P18825 1/20 0.39
PRKCQ Q04759 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1102295 1.00 MEN1 (0.55) MEN1KMT2AGFERPKMTSHR
Tert-Butyl Formate SCHEMBL28793137 0.87 MEN1 (0.43) MEN1KMT2AGFERPKMTSHR
Tert-Butyl Formate SCHEMBL27942261 0.87 MEN1 (0.43) MEN1KMT2AGFERPKMTSHR
SCHEMBL3694593 0.85 MAPK13 (0.47) MEN1KMT2AGFERMAPK13MAPK12
SCHEMBL3694591 0.85 MAPK13 (0.47) MEN1KMT2AGFERMAPK13MAPK12
SCHEMBL1101644 0.84 KMT2A (0.55) MEN1KMT2AGFERPKMTSHR
SCHEMBL1101642 0.84 KMT2A (0.55) MEN1KMT2AGFERPKMTSHR
SCHEMBL1089608 0.81 NPSR1 (0.63) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL1089606 0.81 NPSR1 (0.63) MEN1KMT2AALDH1A1LMNAHTT
SCHEMBL1090965 0.79 MEN1 (0.45) MEN1KMT2AGFERPKMTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2170866-B1 PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC (US) 2014-08-13 EP disclosed
EP-2170866-A1 PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Amgen Inc. (US) 2010-04-07 EP disclosed
US-20090048259-A1 Phthalazine compounds, compositions and methods of use AMGEN INC. (US) 2009-02-19 US disclosed
WO-2009002469-A1 PHTHALAZINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AMGEN INC. (US) 2008-12-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048259-A1 Phthalazine compounds, compositions and methods of use VHL, HDAC5, SUZ12 MEN1 471/4885KMT2A 670/4885GFER 3186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.